This study investigates solid tumors with MTAP deletion. It looks at how the investigational medication works in people with these tumors.
The study evaluates the safety and effects of the investigational medication. It focuses on how the body processes the medication and its potential impact on the tumors.
- Who can participate: Adults aged 18 and older with a solid tumor that has an MTAP gene deletion may participate. Participants need to have unresectable or metastatic disease and meet certain health criteria.
- Study details: Participants will receive the investigational medication to check its effects on their tumors. Some might receive a placebo, which is an inactive substance that looks like the investigational medicine but does not contain any medicine.